Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of sunitinib malate in treating
human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral
therapy. Sunitinib malate may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.